OSE Immunotherapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

OSE ImmunotherapeuticsDie Umsatzerlöse und Gewinne des Unternehmens werden voraussichtlich um 45.8% bzw. 58.1% pro Jahr zurückgehen. Der Gewinn pro Aktie wird voraussichtlich zurückgehen um 58.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -19.4% betragen.

Wichtige Informationen

-58.1%

Wachstumsrate der Gewinne

-58.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	15.1%
Wachstumsrate der Einnahmen	-45.8%
Zukünftige Eigenkapitalrendite	-19.4%
Analystenabdeckung	Low
Zuletzt aktualisiert	27 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

OSE Immunotherapeutics SA (EPA:OSE) Analysts Are Way More Bearish Than They Used To Be

May 11

Is OSE Immunotherapeutics (EPA:OSE) A Risky Investment?

May 08

Imagine Holding OSE Immunotherapeutics (EPA:OSE) Shares While The Price Zoomed 322% Higher

Mar 16

How Is OSE Immunotherapeutics' (EPA:OSE) CEO Paid Relative To Peers?

Dec 01

Gewinn- und Umsatzwachstumsprognosen

ENXTPA:OSE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	16	-29	-24	N/A	2
12/31/2025	55	51	0	N/A	3
12/31/2024	78	74	80	N/A	3
6/30/2024	83	46	N/A	N/A	N/A
3/31/2024	43	12	N/A	N/A	N/A
12/31/2023	2	-23	-20	-20	N/A
9/30/2023	3	-25	-24	-24	N/A
6/30/2023	4	-28	-28	-28	N/A
3/31/2023	11	-23	-23	-23	N/A
12/31/2022	18	-18	-19	-18	N/A
9/30/2022	26	-13	-12	-12	N/A
6/30/2022	33	-7	-6	-5	N/A
3/31/2022	30	-12	-8	-8	N/A
12/31/2021	26	-17	-10	-10	N/A
9/30/2021	20	-21	-14	-13	N/A
6/30/2021	14	-25	-17	-17	N/A
3/31/2021	12	-21	-18	-18	N/A
12/31/2020	10	-17	-20	-20	N/A
9/30/2020	13	-12	-17	-17	N/A
6/30/2020	16	-8	-14	-14	N/A
3/31/2020	21	-6	-3	-2	N/A
12/31/2019	26	-5	9	9	N/A
9/30/2019	23	-4	8	9	N/A
6/30/2019	20	-3	8	8	N/A
3/31/2019	22	1	4	5	N/A
12/31/2018	24	5	0	1	N/A
9/30/2018	24	5	-1	0	N/A
6/30/2018	24	5	-3	-2	N/A
3/31/2018	16	-3	N/A	-5	N/A
12/31/2017	7	-11	N/A	-8	N/A
9/30/2017	5	-10	N/A	-2	N/A
6/30/2017	3	-10	N/A	4	N/A
3/31/2017	2	5	N/A	2	N/A
12/31/2016	0	21	N/A	1	N/A
9/30/2016	0	21	N/A	-2	N/A
6/30/2016	0	22	N/A	-5	N/A
3/31/2016	0	8	N/A	-5	N/A
12/31/2015	0	-6	N/A	-5	N/A
9/30/2015	0	-5	N/A	-4	N/A
6/30/2015	0	-5	N/A	-3	N/A
3/31/2015	0	-4	N/A	-3	N/A
12/31/2014	N/A	-3	N/A	-2	N/A
9/30/2014	N/A	-2	N/A	-1	N/A
6/30/2014	N/A	-1	N/A	-1	N/A
3/31/2014	N/A	-1	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: OSEFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-58.1% pro Jahr).

Ertrag vs. Markt: OSEFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-58.1% pro Jahr).

Hohe Wachstumserträge: OSEFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.

Einnahmen vs. Markt: OSEDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-45.8% pro Jahr).

Hohe Wachstumseinnahmen: OSEDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-45.8% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: OSE wird voraussichtlich in 3 Jahren unrentabel sein.

OSE Immunotherapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 42% to €10.15

Forecast breakeven date moved forward to 2024

Consensus revenue estimates increase by 59%

Forecast to breakeven in 2025

Consensus revenue estimates fall by 73%

Forecast breakeven date moved forward to 2024

Recent updates

New major risk - Revenue and earnings growth

Price target increased by 42% to €10.15

New major risk - Revenue and earnings growth

OSE Immunotherapeutics Presents Preclinical Data on Mrna Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders At the Focis Annual Meeting, San Francisco

Forecast breakeven date moved forward to 2024

Would OSE Immunotherapeutics (EPA:OSE) Be Better Off With Less Debt?

OSE Immunotherapeutics SA, Annual General Meeting, Jun 19, 2024

Consensus revenue estimates increase by 59%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2025

OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors

New minor risk - Shareholder dilution

OSE Immunotherapeutics SA and Nantes University Hospital Presents Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

Ose Immunotherapeutics Sa Announces First Clinical Results for Bi 770371, A Novel Anti-Sirpa Monoclonal Antibody

Consensus revenue estimates fall by 73%

We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt

First half 2023 earnings released: €0.64 loss per share (vs €0.11 loss in 1H 2022)

New major risk - Financial position

Forecast breakeven date moved forward to 2024

OSE Immunotherapeutics SA Announces Publication in Frontiers in Immunology on Ose-230, Its Novel Agonist Therapy in Chronic Inflammation

OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplantation

Price target decreased by 14% to €10.80

OSE Immunotherapeutics SA Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist

High number of new directors

High number of new directors

OSE Immunotherapeutics SA Appoints Eric Leire as A New Independent Director and Anne-Laure Autret-Cornet as Director

Price target decreased by 7.7% to €12.00

OSE Immunotherapeutics SA Presents Clinical Abstracts on Tedopi at the ASCO 2023 Annual Meeting

OSE Immunotherapeutics SA, Annual General Meeting, Jun 22, 2023

OSE Immunotherapeutics and GERCOR Oncology Clinician Group Announces Completion of Patient Enrollment in TEDOPaM Phase 2 Clinical Trial with Tedopi in Advanced Pancreatic Cancer

Forecast to breakeven in 2025

We Think OSE Immunotherapeutics (EPA:OSE) Has A Fair Chunk Of Debt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

OSE Immunotherapeutics SA Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies

OSE Immunotherapeutics SA Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas

Consensus forecasts updated

Price target decreased to €15.03

OSE Immunotherapeutics SA Announces Latest Preclinical Efficacy Data on its Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting

Ose Immunotherapeutics Announces Publication of Peer-Reviewed Data on Clec-1

Servier and OSE Immunotherapeutics Announce Completion of Patient Enrollment in the Phase 2a Clinical Trial of OSE-127/S95011 in Primary Sjögren’s Syndrome

OSE Immunotherapeutics SA Updates on Tedopi®, Cancer Vaccine as Potential New Standard of Care in Non-Small Cell Lung Cancer After Failure to Immunotherapies

OSE Immunotherapeutics SA Appoints Nicolas Poirier as Chief Executive Officer

First half 2022 earnings released: €0.11 loss per share (vs €0.64 loss in 1H 2021)

Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022

Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022

OSE Immunotherapeutics SA Appoints Alexis Vandier as Chief Executive Officer

OSE Immunotherapeutics SA, Annual General Meeting, Jun 23, 2022

OSE Immunotherapeutics SA Appoints its International Scientific Advisory Board

OSE Immunotherapeutics SA (EPA:OSE) Analysts Are Way More Bearish Than They Used To Be

Consensus forecasts updated

Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPa Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology

OSE Immunotherapeutics SA Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target for Cancer Immunotherapy

OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy

No longer forecast to breakeven

OSE Immunotherapeutics SA to Report Fiscal Year 2021 Results on Mar 30, 2022

Boehringer Ingelheim and OSE Immunotherapeutics to Present Biomarker Analyses From the Phase 1 Clinical Trial With First-in-Class SIRPa Inhibitor BI 765063 in Advanced Solid Tumors

OSE Immunotherapeutics SA Appoints Alexandre Lebeaut as Independent Member of the Board of Directors

OSE Immunotherapeutics SA Announces Acceptance of the US Investigational New Drug Application Obtained by Veloxis Pharmaceuticals, Inc., Its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients

OSE Immunotherapeutics SA Announce the Continuation of Its Phase 2 Trial Testing Anti-Il-7 Receptor Antagonist OSE-127/S95011 in Ulcerative Colitis After the Interim Futility Analysis

OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, Its Multi-Target T-Cell Anti-COVID Vaccine

First half 2021 earnings released: €0.64 loss per share (vs €0.21 loss in 1H 2020)

OSE Immunotherapeutics SA to Present Phase 1 Results with First-In-Class Sirpa Inhibitor Bi 765063 in Advanced Solid Tumors At Esmo 2021

OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi in Combination with Pembrolizumab in Ovarian Cancer

Servier and OSE Immunotherapeutics SA Announces Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

OSE Immunotherapeutics SA Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study

Ose Immunotherapeutics and the Fort Foundation Announce Initiation of A Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (Nivolumab) in Non-Small Cell Lung Cancer

OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine

OSE Immunotherapeutics SA and Boehringer Ingelheim to Present Positive Phase 1 Results with First-In-Class Sirpa Inhibitor Bi 765063 in Advanced Solid Tumors At Asco 2021